These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 31898276)

  • 1. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
    Paolicelli D; Manni A; Iaffaldano A; Trojano M
    CNS Drugs; 2020 Jan; 34(1):65-92. PubMed ID: 31898276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of ozanimod
    Paul D; Swallow E; Patterson-Lomba O; Branchcomb T; N'Dri L; Gomez-Lievano A; Liu J; Dua A; McGinley M
    Ther Adv Neurol Disord; 2024; 17():17562864241237856. PubMed ID: 38855023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    CNS Drugs; 2013 Aug; 27(8):591-609. PubMed ID: 23801528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
    Pham Nguyen TP; Jacobs D; Thibault D; Willis AW
    Mult Scler Relat Disord; 2021 Jul; 52():102944. PubMed ID: 33894480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 18. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.